Table 1 The characteristics of included studies. CHD Coronary heart disease; DM diabetes mellitus; CAG coronary angiography; PCI percutaneous coronary intervention; PAG peripheral angiography; PTA percutaneous transluminal angioplasty; CECT contrast-enhanced computerised tomography; M male; F female; NS normal saline; d day; h hour; min minute; iv intravenous injection.
First author | Publication year | Sample size | Age (years) | Object of study | NO. of CIN (case/control) | Observation index | Experimental group treatment strategy(alprostadil) | Jadad score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case(M/F) | Control(M/F) | Case | Control | BUN | CysC | Scr | ||||||
Franz RW[11] | 2011 | 20(12/8) | 21(17/4) | 48–87 | 48–87 | vascular surgery | 0/1 | oral 200 μg preoperative | 4 | |||
Li B[24] | 2011 | 34(34/0) | 26(26/0) | 69.4 ± 7.3 | 67.9 ± 6.8 | CHD CAG/PCI | 2/3 | 48 h | 48 h | 20 μg + NS 20 ml iv qd, 30 min preoperative, continue 3d postoperative | 2 | |
Li JZ[25] | 2016 | 50(33/17) | 53(34/19) | 58.11 ± 9.7 | 56.84 ± 9.29 | CHD PCI | 1/6 | 24 h,72 h | 10 μg + NS 100 ml iv drip qd, 1d preoperative, 3d postoperative | 2 | ||
Liu H[26] | 2013 | 30(16/14) | 30(15/15) | 55–74 | 55–75 | DM PAG | 0/0 | 24 h,48 h | 24 h,48 h | 10 μg + NS 10 ml iv qd, 3d preoperative | 3 | |
Liu Y[27] | 2011 | 29(16/13) | 29(19/10) | 57.0 ± 7.5 | 59.4 ± 9.2 | CHD CAG/PCI | 4/13 | 48 h,72 h | 48 h,72 h | 10 μg + NS 50 ml iv pumping bid, 7d postoperative | 2 | |
Liu YY[28] | 2011 | 82(51/31) | 84(51/33) | 60.8 ± 12.5 | 61.7 ± 12.8 | CHD CAG/PCI | 2/3 | 48 h | 20 ng/kg/min, continue 6 h postoperative | 2 | ||
Li XY[29] | 2013 | 14(8/6) | 15(11/4) | 66 ± 12 | 66 ± 12 | DM PAG or PTA | 0/2 | 24 h,72 h | 24 h,72 h | 2 ng/kg/min, continue 6 h preoperative and 20 μg + NS 40 ml iv qd, the second day, 5d postoperative | 3 | |
Li YN[30] | 2014 | 150(96/54) | 150(54/96) | 68.02 ± 7.03 | 68.49 ± 6.10 | CHD CAG/PCI | 4/13 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 0.5-1 h preoperative, 3d postoperative | 3 | |
Miao Y[31] | 2013 | 154(120/34) | 176(133/43) | 79.08 ± 6.16 | 78.26 ± 6.61 | CECT | 14/39 | 24 h,48 h,72 h | 24 h,48 h,72 h | 0.4 μg/kg/day, 48 h preoperative, continue to 48 h postoperative | 4 | |
Su C[32] | 2015 | 55(35/20) | 51(33/18) | 62.7 ± 10.8 | 63.5 ± 11.2 | CHD PCI | 2/7 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 1 day preoperative, 3d postoperative | 2 | |
Wang L[33] | 2016 | 50(31/19) | 50(32/18) | 60.48 ± 4.51 | 60.5 ± 4.17 | CHD CAG/PCI | 2/8 | 72 h | 72 h | 20 μg + NS 40 ml iv drip qd, 30 min preoperative,0.5,1, 2d postoperative | 2 | |
Wang ZD[34] | 2015 | 65(49/16) | 63(48/15) | 58.2 ± 10.8 | 59.1 ± 11.2 | CHD CAG/PCI | 7/17 | 24 h,48 h,72 h | 24 h,48 h,72 h | 10 μg + NS 20 ml iv qd preoperative, 7d postoperative | 3 | |
Xu R[35] | 2012 | 30(13/17) | 30(12/18) | 60 ± 9 | 60 ± 11 | CHD CAG/PCI | 2/10 | 24 h,48 h | 10 μg + NS 20 ml iv qd, preoperative, 7d postoperative | 2 | ||
Yan HY[36] | 2014 | 21(12/9) | 19(11/8) | 73.3 ± 6.3 | 75.1 ± 8.5 | PAG | 4/8 | 24 h,48 h,72 h | 24 h,48 h,72 h | 24 h,48 h,72 h | 10 μg + NS 10 ml iv bid, 3d postoperative | 2 |
Ye Y[37] | 2006 | 28(25/3) | 30(26/4) | 70.28 ± 5.6 | 72.62 ± 9.15 | PAG/CECT | 6/14 | 48 h,72 h | 48 h,72 h | 20 μg + NS 20 ml iv, qd, 3d postoperative | 2 | |
Zhao HW[38] | 2014 | 58(31/27) | 58(39/19) | 64 ± 9 | 65 ± 8 | CHD DM PCI | 2/9 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 1d preoperative, 4d postoperative | 2 | |
Zhong SG[39] | 2014 | 50(38/12) | 50(39/11) | 63.9 ± 7.6 | 64.1 ± 8.0 | CHD DM PCI | 1/8 | 72 h | 72 h | 100 μg + NS 100 ml iv drip bid, 3d postoperative | 2 | |
Zhou DC[40] | 2013 | 112(65) | 103(61) | 62.1 ± 11.1 | 63.2 ± 10.9 | CHD CAG/PCI | 8/19 | 10 μg + NS 10 ml iv bid, 1d postoperative, 7-10d postoperative | 3 | |||
Zhu L[41] | 2011 | 99(99/0) | 98(98/0) | 57 ± 15 | 57 ± 15 | CHD CAG ± PCI | 7/19 | 48 h | 48 h | 48 h | 20 μg + NS 20 ml iv qd, 10d postoperative | 2 |
